Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118573
Author
Takemori, Toshiyuki Kobe University|Hyogo Cancer Center
Kawamoto, Teruya Kobe University
Hara, Hitomi Kobe University
Fukase, Naomasa Kobe University
Fujiwara, Shuichi Kobe University
Fujita, Ikuo Hyogo Cancer Center
Fujimoto, Takuya Hyogo Cancer Center
Morishita, Masayuki Hyogo Cancer Center
Kitayama, Kazumichi Kobe University
Yahiro, Shunsuke Kobe University
Miyamoto, Tomohiro Kobe University
Saito, Masanori Japanese Foundation for Cancer Research
Sugaya, Jun National Cancer Center Hospital
Hayashi, Katsuhiro Kanazawa University
Kawashima, Hiroyuki Niigata University
Torigoe, Tomoaki Saitama Medical University
Nakamura, Tomoki Mie University
Kondo, Hiroya Okayama University
Wakamatsu, Toru Osaka International Cancer Institute
Watanuki, Munenori Tohoku University
Kito, Munehisa Shinshu University
Tsukushi, Satoshi Aichi Cancer Center Hospital
Nagano, Akihito Gifu University
Outani, Hidetatsu Osaka University
Nishimura, Shunji Kindai University
Kobayashi, Hiroshi The University of Tokyo
Watanabe, Itsuo Tokyo Dental College
Demizu, Yusuke Hyogo Ion Beam Medical Center Kobe Proton Center
Sasaki, Ryohei Kobe University
Fukumoto, Takumi Kobe University
Niikura, Takahiro Kobe University
Kuroda, Ryosuke Kobe University
Akisue, Toshihiro Kobe University
Keywords
pelvis
retroperitoneum
bone and soft tissue sarcoma
prognosis
prognostic factors
Content Type
Journal Article
Description
We aimed to clarify the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma. The 3-year overall survival (OS), local control (LC) rate, and progression-free survival (PFS) were 71.7%, 79.1%, and 48.6%, respectively. The most influential poor prognostic factor for OS was distant metastasis, and for PFS, this was higher age (≥60 years). Larger primary tumor size (≥10 cm) was the only poor prognostic factor for LC. In the histological analysis, osteosarcoma showed significantly worse OS and PFS than other sarcomas in the pelvis and retroperitoneum.
Description Alternative
This study aimed to retrospectively analyze the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma (BSTS). Overall, 187 patients with BSTS in the pelvis and retroperitoneal region treated at 19 specialized sarcoma centers in Japan were included. The prognostic factors related to overall survival (OS), local control (LC), and progression-free survival (PFS) were evaluated. The 3-year OS and LC rates in the 187 patients were 71.7% and 79.1%, respectively. The 3-year PFS in 166 patients without any distant metastases at the time of primary tumor diagnosis was 48.6%. Osteosarcoma showed significantly worse OS and PFS than other sarcomas of the pelvis and retroperitoneum. In the univariate analyses, larger primary tumor size, soft tissue tumor, distant metastasis at the time of primary tumor diagnosis, P2 location, chemotherapy, and osteosarcoma were poor prognostic factors correlated with OS. Larger primary tumor size, higher age, soft tissue tumor, chemotherapy, and osteosarcoma were poor prognostic factors correlated with PFS in patients without any metastasis at the initial presentation. Larger primary tumor size was the only poor prognostic factor correlation with LC. This study has clarified the epidemiology and prognosis of patients with pelvic and retroperitoneal BSTS in Japan.
Journal Title
Cancers
ISSN
20726694
Publisher
MDPI
Volume
14
Issue
12
Start Page
3023
Published Date
2022-06-20
Rights
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences